<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842565</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-178R</org_study_id>
    <nct_id>NCT04842565</nct_id>
  </id_info>
  <brief_title>cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria</brief_title>
  <official_title>Phase II Trial of cTACE Plus Sintilimab for Treatment of Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of Sintilimab plus Transcatheter arterial&#xD;
      chemoembolization (TACE) in participants with Intermediate-stage unresectable hepatocellular&#xD;
      carcinoma with Beyond Up-to-seven Criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival time (mPFS) (mRECIST)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The progression-free survival time (mPFS) is defined as the date from the first TACE to the date of first documented disease progression as assessed by mRECIST or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Overall survival (OS) after enrollment is defined as the first TACE to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) by RECIST 1.1 and mRECIST</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Objective Response Rate according to mRECIST and RECIST 1.1 for HCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time (mPFS) (RECICL)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The progression-free survival time (mPFS) is defined as the first time TACE to the date of first documented disease progression as assessed by RECICL or death, whichever comes earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Time to Progression (TTP) is defined as the time from first TACE to the date of the first documented tumor progression according to the definition above.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE+Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab (200mg ivdrip D1 Q3W)</description>
    <arm_group_label>TACE+Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.</description>
    <arm_group_label>TACE+Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥20 and ≤75 years old&#xD;
&#xD;
          2. Clinically diagnosed or pathologically confirmed advanced hepatocellular carcinoma. (&#xD;
             Fibrolamellae and mixed hepatocellular/cholangiocarcinoma subtypes are not included)&#xD;
&#xD;
          3. CNLC stage IIa/IIb or BCLC stage B, not eligible for resection or local ablation,&#xD;
             beyond up-to-seven criteria (hepatocellular carcinomas with seven as the sum of the&#xD;
             size of the largest tumor [in cm] and the number of tumors)&#xD;
&#xD;
          4. Newly diagnosed or recurrent more than half a year after radical surgery&#xD;
&#xD;
          5. No prior TACE treatment,&#xD;
&#xD;
          6. Child-Pugh A, ECOG PS: 0-1&#xD;
&#xD;
          7. Patients with chronic HBV infection must have HBV DNA viral load &lt; 500 IU/mL at&#xD;
             screening. In addition, they must be on antiviral therapy per regional standard of&#xD;
             care guidelines prior to initiation of study therapy.&#xD;
&#xD;
          8. At least one measurable site of disease as defined by modified RECIST (mRECIST) and&#xD;
             RECICL criteria with spiral CT scan or MRI.&#xD;
&#xD;
          9. Life expectancy of at least 3 months.&#xD;
&#xD;
         10. Adequate blood count, liver-enzymes, and renal function: Haemoglobin ≥ 8.5 g/dL,&#xD;
             absolute neutrophil count ≥ 1,500/L, platelets ≥70 x103/L; Total bilirubin ≤ 3x upper&#xD;
             normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x&#xD;
             upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31&#xD;
             g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30&#xD;
             mL/min (if using the Cockcroft-Gault formula )&#xD;
&#xD;
         11. Patients are willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment, adherence to contraceptive measures, scheduled&#xD;
             visits and examinations including follow up.&#xD;
&#xD;
         12. Normal T3 and T4. (T3 and T4 controlled in the normal range through treatment is also&#xD;
             eligible.)&#xD;
&#xD;
         13. Female patients with reproductive potential must have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to start of trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diffuse HCC or presence of vascular invasion or extrahepatic spread.&#xD;
&#xD;
          2. The patient suffered from other malignant tumors in the past 3 years or at the same&#xD;
             time (except for cured skin basal cell carcinoma and cervical carcinoma in situ).&#xD;
&#xD;
          3. Known history of hepatic encephalopathy within 6 months&#xD;
&#xD;
          4. Known history of cardiac disease within 12 months before the first dose of study drug.&#xD;
&#xD;
          5. Clinically significant hemoptysis or tumor bleeding of any reason within 2 weeks&#xD;
             before the first dose of study drug.&#xD;
&#xD;
          6. Severe unhealed wounds, ulcers, or fractures&#xD;
&#xD;
          7. Prior systemic anti-cancer therapy.&#xD;
&#xD;
          8. Prior treatment with TACE.&#xD;
&#xD;
          9. Suffer from high blood pressure and cannot be well controlled by antihypertensive&#xD;
             drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg)&#xD;
&#xD;
         10. Any active autoimmune disease or a history of autoimmune disease.&#xD;
&#xD;
         11. Major surgery within 4 weeks of starting the study treatment OR subjects who have not&#xD;
             recovered from effects of major surgery.&#xD;
&#xD;
         12. History of allogeneic tissue/solid organ transplant.&#xD;
&#xD;
         13. Urine routine test showed urine protein ≥ ++ and confirmed 24-hour urine protein&#xD;
             content&gt; 1.0 g.&#xD;
&#xD;
         14. Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-PD-L1,&#xD;
             anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member&#xD;
             of the Tumor Necrosis Factor Receptor (TNFR) family), or anti-Cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any&#xD;
             other antibody or drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways).&#xD;
&#xD;
         15. Female patients who are pregnant, breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng Wang</last_name>
    <phone>64041990</phone>
    <email>wang.zheng@zs-hospital.sh.cn</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>zheng wang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

